Clinical trials: Sjögren's Syndrome
Sjogren Syndrome
Temporomandibular Joint Dysfunction in Sjögren's Syndrome
Study Purpose The purpose of this observational study is to determine the prevalence of temporomandibular dysfunction (TMD) in individuals diagnosed with Sjögren's syndrome and to examine the relationship between disease activity…
- Trial name
- Sjögren (NCT07248306)
- Testing
- Temporomandibular Joint Function
- Where
- Turkey (Türkiye)
- Volunteers
- 27 people
- Sponsor
- Pamukkale University
Primary Sjögren's Syndrome (pSS)
New Clinical End-points in Patients With Primary Sjögren's Syndrome
There are no approved treatments for pSS and the clinical endpoints currently used in clinical trials are inadequate to capture all aspects of the disease that should be evaluated in clinical trials.
- Trial name
- NECESSITY (NCT05113004)
- Testing
- Hydroxychloroquine 400mg/d, Leflunomide 20mg/d, Mycophenolate mofetil 2000mg/d
- Where
- 7 sites in France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primer Sjogren's Syndrome
Investigation of the Effectiveness of Cognitive Exercise Therapy Approach in Patients With Primary Sjögren's Syndrome
To determine the effectiveness of the Cognitive Exercise Therapy Approach (BETY in Turkish) in individuals with Primary Sjögren's Syndrome and to compare the effects of this training when applied in groups and individually.
- Trial name
- NCT06398210
- Testing
- Cognitive Exercise Therapy Approach (BETY)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Sjogren's Syndrome
EVADRY® in the Treatment of Xerostomia in Sjögren's Syndrome
Xerostomia is a common and very bothersome manifestation that impairs the quality of life in Sjogren's syndrome. Symptomatic therapeutic alternatives for this syndrome are limited in Tunisia.
- Trial name
- DRYLESS (NCT06313905)
- Testing
- EVADRY
- Volunteers
- 180 people
- Sponsor
- University Tunis El Manar
Primary Sjögren's Syndrome (pSS)
Current Therapy in Primary Sjogren's Syndrome
Purpose:The aim of the study was to investigate the effectiveness of interferential current therapy on salivary gland function in Primary Sjogren's Syndrome (pSS). Methods:Thirty six pSS were included in the study.
- Trial name
- NCT06989411
- Testing
- Clinical pilates exercises +Interferential current therapy (real current)
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Pamukkale University
Primary Sjögren's Syndrome (pSS)
JH013 Injection in Patients With Primary Sjögren's Syndrome
This is a multicenter, open-label, single-arm Phase I study consisting of two parts: Part A, a single-dose dose-escalation phase, and Part B, a multiple-dose dose-escalation phase.
- Trial name
- NCT07818694
- Testing
- JH013 injection
- Volunteers
- 54 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Sjogren's Syndrome
Sjogren's Mini-Pill Oral and Gut Microbiome Study
The goal of this observational study is to characterize and compare region-specific gastrointestinal, stool, oral, and periodontal microbiomes in adults with Sjögren's disease and healthy controls using ingestible mini-pill…
- Trial name
- NCT07732582
- Testing
- Mini-Pill
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Tufts University
Primary Sjögren's Syndrome
Primary Sjögren Syndrome
Primary Sjögren syndrome (pSS) is an inflammatory, autoimmune, multiorgan disease often involving the central and peripheral nervous systems.
- Trial name
- NeuroSenSS (NCT01989819)
- Testing
- skin biopsy
- Where
- 7 sites in France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Sjogren Syndrome, Sjogren Disease
TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE
Sjögren's disease (SjD) is a chronic, immune-mediated, systemic inflammatory disease characterized mainly by involvement of the salivary and lacrimal glands, causing symptoms of sicca syndrome.
- Conditions
- Sjogren Syndrome, Sjogren Disease, Primary Sjogren Syndrome
- Trial name
- VaLS (NCT07153276)
- Testing
- Fractional CO2 laser (vaginal), Promestriene Vaginal
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Primary Sjögren's Syndrome
Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
The purpose of this study was to investigate adaptation, validity, and reliability of the Turkish version of the Primary Sjögren's Syndrome Quality of Life (PSS-QoL) Questionnaire
- Trial name
- NCT04858464
- Testing
- Survey study
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Gazi University
Primary Sjögren's Syndrome (pSS)
Diagnostic Suspicion of Primitive Syndrome Sjögren's : Brest Cohort
This study aims to evaluate the diagnosis performance of several item used for the classification, the diagnosis and the prognostic of pSS (primary Sjogren syndrome)
- Trial name
- DIApSS (NCT03681964)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Dry Eye Disease
Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom
To study the effectiveness of 0.05% cyclosporine A eye drops in combination with smart plug absorbable lacrimal duct plugs in the monotherapy of cyclosporine for SSDE.
- Trial name
- NCT07171710
- Testing
- 0.05% Cyclosporine Eye Drops, Smart plug absorbable lacrimal duct plugs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Eye Hospital
Sjogren's Syndrome
Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome
The ANISE-II study is a randomized, double-blind, placebo-controlled phase IIa proof-of-concept trial. Thirty patients with primary Sjögren's syndrome (pSS) are randomized in a 2:1 ratio to either anifrolumab or placebo treatment…
- Trial name
- ANISE-II (NCT05383677)
- Testing
- Anifrolumab
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Primary sjögren's Syndrome
Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
Salivary gland ultrasonography is identified as a valuable diagnostic tool and potential criteria item for disease classification of sjögren's syndrome and evaluate evolution of parenchyma.
- Trial name
- MASAÏ (NCT04212572)
- Where
- 3 sites in France
- Volunteers
- 242 people
- Sponsor
- University Hospital, Brest
Healthy, Idiopathic Inflammatory Myopathies
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases.
- Conditions
- Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease
- Trial name
- NCT07284797
- Testing
- XmAb657
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Sjogren's Syndrome
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525).
- Trial name
- TWINSS Extn (NCT04541589)
- Testing
- Iscalimab
- Where
- 62 sites in United States, Argentina and 21 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjögren's Syndrome
The ASSESS National Multi-center Prospective Cohort
The ASSESS national multi-center prospective cohort (Assessment of Systemic complications (Signs) and Evolution in Sjögren's Syndrome "SS") was set up in 2006 thanks to a grant of the French Ministry of Health.
- Trial name
- ASSESS (NCT03040583)
- Testing
- No intervention
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sjögren's Disease
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
- Trial name
- NCT07836660
- Testing
- Part B -Telitacicept, Part A - IBI355
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Sjogren Syndrome
Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies
Unexplained fatigue is a frequent (60-70%) chronic complaint in Sjögren's syndrome (SjS) with a clear unmet therapeutic need, despite the recommendation of adapted physical activity (APA) programs, which are effective and…
- Trial name
- FESSONA (NCT06875102)
- Testing
- Acupuncture (ACU), Transcutaneous Vagus Nerve Stimulation (tVNS), APA (adapted physical activity )
- Where
- France
- Volunteers
- 174 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Sjogren's Syndrome
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of…
- Trial name
- NCT02631538
- Testing
- Belimumab, Rituximab
- Where
- 36 sites in Argentina, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline